Oncolytics Biotech Inc T.ONC

Gap Open @ C$ 1.86

[Noteable]

followed by another at C$3.70 with warrants expirng tomorrow.

[13X2413]

Followed by you waking up from Fantasy Land. 

[Noteable]

Yez boss. LOL!!

[Noteable]

Whacha still doin' here boss?? You and Quentin were long gone boyz. lol !!

[13X2413]

Still here and hoping for that miracle. 

[Noteable]

Lottsa room for one or two with 2 and potentially 3 registration studies now being pursued both in monotherapy and in combination with other I/O agents. The monotherapy registration study offers ONCY the freedom to operate and removes any restriction for the company to partner with one Big Pharma company or another.

[Noteable]

By ONCY beginning the process of enrolling between 180-200 patients in a monotherapy pelareorep + paclitaxel clinical/registration study ONCY speeds up the Accelerated Approval process by demonstrating to the FDA that ONCY is well into the implementation of a well designed clinical study, with FDA agreed upon primary and secondary endpoints, that have resulted in previous Accelerated Approvals, as

[m00nsh0ts]

Notable, you must be schizophrenic One minute you're talking about how bad the management is and now you're talking about them running the study. They have fouled up every trial that they've run. I wouldn't trust them to run a street survey much less clinical trial.

[Noteable]

m00nsh0ts - you're confused once again. Show me one time that I was critical of management. 

[Noteable]

The problem I had was with Andrew De G. - who was hired by Matt. Now both are effectively gone.

[Noteable]

PrECOG, LLC. ran ONCY's Bracelet-1 study, enrolling 18 medical centers, from Eastern, N,E  and S.E USA. - from New York to Illinois to Florida. ONCY did not run the trial. These medical centers were those that Pfizer and Roche have regularly used in conducting their clinical studies. This notwithstanding, ONCY management needs involvement in the final interpretation of the data. https

[Noteable]

Sanofi is the only other recognizable/responsible company that had used PrECOG to run a clinical trial. Sanofi trialed their PARP inhibitor in TNBC. As mentioned on this message board many times, ONCY's pelareorep is synergistic with PARP inhibitors. 2023 paper : PARP inhibitors enhance reovirus-mediated cell killing through the deathinducing signaling complex (DISC) with an associated NF-κB

[m00nsh0ts]

I've never understood the Sanofi connection or the disturbing lack there of.

[Noteable]

Wayne Pisano and a former ONCY director Mark Leivonen were both CEOs of Sanofi in Canada 

[m00nsh0ts]

And because of the apparent complete lack of interest from Sanofi It makes it seem like there is nothing here to look at by other BP.

[Noteable]

Alternatively, the 2 and possibly 3 registration studies looking at Accelerated Approvals gives BP companies like Sanofi,  plenty to look at now. 

[Noteable]

Just so that you don't lose focus, An Accelerated Approval results in the creation of a revenue stream for ONCY and an accretive asset for any Big Pharma acquirer of ONCY.  And because of this capital opportunity eventually happening, I think that the latter Big Pharma acquisition will happen sooner than later and well before an Accelerated Approval is even announced.